# Study of Peripheral Neuropathy in Patients With Advanced Urothelial Cancer Treated With Enfortumab Vedotin and Pembrolizumab With Supportive Neuridase (ENDEAVOR)

> **NCT07629700** · NA · NOT_YET_RECRUITING · sponsor: **University of Florence** · enrollment: 40 (estimated)

## Conditions studied

- Urothelial Carcinoma (UC)
- Peripheral Nerve Disease

## Interventions

- **DRUG:** enfortumab vedotin (EV)
- **DRUG:** PEMBROLIZUMAB (alone or when added to a regimen above)
- **OTHER:** Neuridase

## Key facts

- **NCT ID:** NCT07629700
- **Lead sponsor:** University of Florence
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2027-09-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07629700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07629700, "Study of Peripheral Neuropathy in Patients With Advanced Urothelial Cancer Treated With Enfortumab Vedotin and Pembrolizumab With Supportive Neuridase (ENDEAVOR)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07629700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*